2016
DOI: 10.1111/head.12981
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of Noninvasive Brain Stimulation on Pain Control in Migraine Patients: A Systematic Review and Meta‐Analysis

Abstract: Low or very low quality of evidence suggests that our primary outcome evaluation failed to find support for the superiority of NIBS over sham treatment. Although, subgroup analysis reveals that tDCS have moderate to high effects and could be a promising nonpharmacological alternative to pain control, mainly for painkiller intake reduction. However, there is a need for larger controlled trials with methodological rigor, which could increase the power of result inference.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
54
0
3

Year Published

2017
2017
2023
2023

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 59 publications
(59 citation statements)
references
References 37 publications
1
54
0
3
Order By: Relevance
“…For example, there is good evidence that EBS is effective in major depression [15], but not fibromyalgia pain [16], food craving and consumption [17], Parkinson’s disease [18] and stroke aphasia [19]. A common finding from these meta-analyses is that EBS studies are often of low research quality [20, 21] and that, when present, EBS effects are often small [2024]. For example, EBS reduces chronic pain by only 12% (95% CI 8% to 15%), below the threshold for a minimal clinically important difference [22], and anodal EBS is associated with a significant reduction in reaction time, but the magnitude of this effect is small (Hedges’ g: −0.10, 95% CI −0.16 to −0.04) [24].…”
Section: Discussionmentioning
confidence: 99%
“…For example, there is good evidence that EBS is effective in major depression [15], but not fibromyalgia pain [16], food craving and consumption [17], Parkinson’s disease [18] and stroke aphasia [19]. A common finding from these meta-analyses is that EBS studies are often of low research quality [20, 21] and that, when present, EBS effects are often small [2024]. For example, EBS reduces chronic pain by only 12% (95% CI 8% to 15%), below the threshold for a minimal clinically important difference [22], and anodal EBS is associated with a significant reduction in reaction time, but the magnitude of this effect is small (Hedges’ g: −0.10, 95% CI −0.16 to −0.04) [24].…”
Section: Discussionmentioning
confidence: 99%
“…tDCS, using a portable, hand‐held device, can modulate pain‐related neural networks . It has also been shown to cause reduction of analgesic drug intake with pain, and has minimal adverse events …”
Section: Emerging Noninvasive Neuromodulation For Migraine Preventionmentioning
confidence: 99%
“…20 It has also been shown to cause reduction of analgesic drug intake with pain, and has minimal adverse events. 21,22 Fifty adult women with migraine with or without aura who were refractory to pharmacological therapy were enrolled to either continue to receive their current pharmacological treatment vs augment current treatment with tDCS. 23 Thirty subjects received 10 procedures of tDCS over 30 days, with each treatment stimulation being given over M1 of the subject's dominant hemisphere for 20 minutes.…”
Section: Emerging Noninvasive Neuromodulation For Mig Raine Preventionmentioning
confidence: 99%
“…Few data are available from randomized sham-controlled studies to evaluate the efficacy of tDCS devices; however, subgroup analysis from a recent meta-analysis of noninvasive brain stimulation found moderate quality evidence suggesting that tDCS reduced pain intensity, number of migraines, and "painkiller" intake. 22 The Cefaly device has been shown in RCTs to be of benefit for both abortive and preventive therapy and is FDA approved for the prevention of episodic migraine. The gammaCore device (a peripheral vagal nerve stimulator) has shown efficacy in RCTs as an acute treatment for episodic and chronic migraines.…”
Section: New Developments In Established Migraine Treatmentsmentioning
confidence: 99%